CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Rituximab

Rituximab

Last Updated: June 26, 2006

Result type: Reports

Project Number: SR0068-000

Product Line: Reimbursement Review

Generic Name: Rituximab

Brand Name: Rituxan

Manufacturer: Hoffmann-La Roche Limited

Therapeutic Area: Arthritis, Rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 14, 2007

Recommendation Type: List with clinical criteria and/or conditions

Rituximab

Files